Hyaluronic acid-engineered Bcl-2 inhibitor nanocrystals for site-specific delivery to breast tumor cells
Abstract
Aim: This investigation aims to repurpose venetoclax using hyaluronic acid-coated venetoclax nanocrystals (HA-VEN-NCs) to target breast cancer. Materials & methods: An antisolvent precipitation method was used to fabricate the nanocrystals and optimize them using central composite design. Hyaluronic acid (HA)-coated and -uncoated nanocrystals were compared in terms of in vitro drug release, cell line studies, CD44-expressing breast tumor cell binding capability and anticancer activity. Results: HA-VEN-NCs and venetoclax nanocrystals (VEN-NCs) showed pH-responsive drug-release behavior, exhibiting sustained release at pH 6.8. Our extensive in vitro cell line investigation showed that HA-VEN-NCs efficiently bind to CD44-expressing breast tumor cells and possess excellent anticancer activity (IC50: 2.00 μg/ml) compared with VEN-NCs. Conclusion: Our findings anticipate that HA-VEN-NCs could serve as valuable nanoplatforms for cancer treatments in the future.
Graphical abstract
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. World Health Organization. Breast Cancer (2021). www.who.int/news-room/fact-sheets/detail/breast-cancer
- 2. . Hyaluronic acid conjugated β-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery. Int. J. Pharm. 483(2), 169–179 (2015).
- 3. A role for bacterial urease in gut dysbiosis and Crohn's disease. Sci. Transl. Med. 9(416), 1–12 (2017).
- 4. Zinc finger protein 831 promotes apoptosis and enhances chemosensitivity in breast cancer by acting as a novel transcriptional repressor targeting the STAT3/Bcl2 signaling pathway. Genes Dis. 9(12), 1162–1177 (2022).
- 5. . Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors. Gene 847(1), 1–15 (2022).
- 6. Multifunctional hybrid nanoparticles in diagnosis and therapy of breast cancer. J. Control. Rel. 352(2), 1024–1047 (2022).
- 7. . Design of sodium lanthanide fluoride nanocrystals for NIR imaging and targeted therapy. Mater. Today Chem. 27(1), 1–26 (2023).
- 8. . Development and evaluation of nanocrystals loaded hydrogel for topical application. J. Drug Deliv. Sci. Technol. 74(4), 1–15 (2022). •• Exhaustive summary about nanocrystals and their characterizations.
- 9. . Nanocrystal technology, drug delivery and clinical applications. Int. J. Nanomed. 3(3), 295 (2008).
- 10. . Molecular nanomedicine towards cancer. J. Pharm. Sci. 101(7), 2271–2280 (2012).
- 11. . Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production. Eur. J. Pharm. Sci. 38(3), 224–229 (2009).
- 12. PH-sensitive delivery vehicle based on folic acid-conjugated polydopamine-modified mesoporous silica nanoparticles for targeted cancer therapy. ACS Appl. Mater. Interface 9(22), 18462–18473 (2017).
- 13. . Hyaluronic acid-decorated laponite® nanocomposites for targeted anticancer drug delivery. Polymers (Basel) 11(1), 1–14 (2019).
- 14. . Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 4(7), 528–539 (2004).
- 15. . Conjugation of paclitaxel to C-6 hexanediamine-modified hyaluronic acid for targeted drug delivery to enhance antitumor efficacy. Carbohydr. Polym. 181(1), 150–158 (2018). •• Indicates that hyaluronic acid is beneficial for drug targeting with enhanced antitumor efficacy.
- 16. . Recent advances in hyaluronic acid-based hydrogels for 3D bioprinting in tissue engineering applications. Smart Mater. Med. 4(1), 59–68 (2023).
- 17. Absorption, metabolism, and functions of hyaluronic acid and its therapeutic prospects in combination with microorganisms: a review. Carbohydr. Polym. 299(1), 1–16 (2023). • Provide comprehensive information about hyaluronic acid, its function in CD44 targeting and how it is significant in site-specific delivery.
- 18. . Light-activated drug release from a hyaluronic acid targeted nanoconjugate for cancer therapy. J. Mater. Chem. B. 7(7), 4843–4853 (2019).
- 19. Hyaluronic acid-shelled acid-activatable paclitaxel prodrug micelles effectively target and treat CD44-overexpressing human breast tumor xenografts in vivo. Biomaterials 84(2), 250–261 (2016).
- 20. Dual-stimuli responsive hyaluronic acid-conjugated mesoporous silica for targeted delivery to CD44-overexpressing cancer cells. Acta Biomater. 23(5), 147–156 (2015).
- 21. . Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia 6(4), 343–353 (2004).
- 22. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor. J. Control. Rel. 162(3), 545–552 (2012).
- 23. PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection. Nanomed. Nanotechnol. Biol. Med. 23(1), 1–12 (2012).
- 24. . Nanocrystal preparation: low-energy precipitation method revisited. Cryst. Growth Des. 13(7), 2766–2777 (2013).
- 25. Advances of combinative nanocrystal preparation technology for improving the insoluble drug solubility and bioavailability. Crystals 12(9), 1–21 (2022). •• Significant article that provide ideas to develop nanocrystals for improving the aqueous solubility of drug cargos.
- 26. . Enhanced penetration and improved therapeutic efficacy of bexarotene via topical liposomal gel in imiquimod induced psoriatic plaque model in BALB/c mice. J. Drug Deliv. Sci. Technol. 58(1), 1–34 (2020).
- 27. . Synthesis and characterization of a multifunctional gold-doxorubicin nanoparticle system for pH triggered intracellular anticancer drug release. Eur. J. Pharm. Biopharm. 119(6), 372–380 (2017).
- 28. . Newly developed topical cefotaxime sodium hydrogels: antibacterial activity and in vivo evaluation. Biomed. Res. Int. 14(3), 1–15 (2016).
- 29. . HPLC-MS/MS shows that the cellular uptake of all-trans-retinoic acid under hypoxia is downregulated by the novel active agent 5-methoxyleoligin. Cells 9(9), 2048–2060 (2020). • Provides information on the quantitative determination of cellular uptake using high-performance liquid chromatography methodology.
- 30. Amalgamated microneedle array bearing ribociclib-loaded transfersomes eradicates breast cancer via CD44 targeting. Biomacromolecules 23(3), 661–675 (2022).
- 31. . Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eur. J. Pharm. Sci. 47(2), 497–505 (2012).
- 32. Measurement of the extracellular pH of solid tumours in mice by magnetic resonance spectroscopy: a comparison of exogenous 19 F and 31 P probes. NMR Biomed. Mater. 8(1), 495–504 (1998).
- 33. . Pathways and mechanisms of venetoclax resistance. Leuk. Lymphoma 58(9), 2026–2039 (2017).
- 34. Rumex vesicarius L. extract improves the efficacy of doxorubicin in triple-negative breast cancer through inhibiting Bcl2, mTOR, JNK1 and augmenting p21 expression. Informat. Med. Unlocked 29(2), 1–10 (2022).
- 35. . Optimization of nanostructured lipid carriers for lutein delivery. Colloid. Surf. A 353(2), 149–156 (2010).